Herein we describe the screening of such a library, in comparison with other fragment sets, against the highly validated Mycobacterium tuberculosis (Mtb) target InhA.8 Mtb is the causative agent of tuberculosis (TB), which is currently the leading infectious disease killer worldwide.9 Isoniazid (INH, Figure 1), a successful frontline TB drug for more than 50 years, targets the NADH‐dependent 2‐trans enoyl–acyl carrier protein (ACP) reductase InhA. Here, INHA is linked to infectious disease.